QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-hold-on-vertex-pharmaceuticals-lowers-price-target-to-445

Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $455...

 vertex-pharmaceuticals-raises-fy2025-sales-guidance-from-11850b-12000b-to-11900b-12000b-vs-11987b-est

Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2025 sales outlook from $11.850 billion-$12.000 billion to $11.900 billion-$12.00...

 vertex-pharmaceuticals-q3-adj-eps-480-beats-456-estimate-sales-3076b-beat-3053b-estimate

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.80 per share which beat the analyst consensus estimate o...

 nvidia-amazon-extend-rally-bitcoin-sinks-to-107000-whats-moving-markets-monday

Wall Street opened the week on a mixed note on Monday.

 vertex-pharmaceuticals-presents-multiple-abstracts-showing-clinical-benefits-of-cftr-modulators-at-north-american-cystic-fibrosis-conference-in-seattle

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the cli...

 reported-earlier-vertex-advances-povetacicept-program-with-fda-rolling-review-for-igan-initiates-olympus-a-phase-2b3-pivotal-study-of-pove-for-the-treatment-of-pmn-and-announces-updated-date-from-ruby-3-trial-accepted-for-late-breaking-american-society-of-nephrology-2025-presentation

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vert...

 vera-therapeutics-lead-kidney-drug-poised-for-2026-launch-in-multi-billion-dollar-market

Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment.

 morgan-stanley-maintains-equal-weight-on-vertex-pharmaceuticals-lowers-price-target-to-438

Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and lowers the price...

 jp-morgan-maintains-overweight-on-vertex-pharmaceuticals-raises-price-target-to-530

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target f...

 servicenow-vertex-pharmaceuticals-and-more-cnbcs-final-trades

Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&...

 citigroup-maintains-buy-on-vertex-pharmaceuticals-raises-price-target-to-575

Citigroup analyst Geoff Meacham maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION